- Home
- ENTO vs BDRX Comparison
ENTO vs BDRX Comparison
Compare ENTO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTO
- BDRX
- Stock Information
- Founded
- ENTO 2014
- BDRX 2000
- Country
- ENTO United States
- BDRX United Kingdom
- Employees
- ENTO N/A
- BDRX N/A
- Industry
- ENTO Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- ENTO Health Care
- BDRX Health Care
- Exchange
- ENTO Nasdaq
- BDRX Nasdaq
- Market Cap
- ENTO 2.9M
- BDRX 2.4M
- IPO Year
- ENTO 2016
- BDRX N/A
- Fundamental
- Price
- ENTO $0.54
- BDRX $4.28
- Analyst Decision
- ENTO
- BDRX Strong Buy
- Analyst Count
- ENTO 0
- BDRX 1
- Target Price
- ENTO N/A
- BDRX $200.00
- AVG Volume (30 Days)
- ENTO 62.4K
- BDRX 16.1K
- Earning Date
- ENTO 11-13-2024
- BDRX 09-30-2024
- Dividend Yield
- ENTO N/A
- BDRX N/A
- EPS Growth
- ENTO N/A
- BDRX N/A
- EPS
- ENTO N/A
- BDRX N/A
- Revenue
- ENTO N/A
- BDRX $104,895.00
- Revenue This Year
- ENTO N/A
- BDRX N/A
- Revenue Next Year
- ENTO N/A
- BDRX N/A
- P/E Ratio
- ENTO N/A
- BDRX N/A
- Revenue Growth
- ENTO N/A
- BDRX N/A
- 52 Week Low
- ENTO $0.19
- BDRX $3.50
- 52 Week High
- ENTO $9.35
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- ENTO 43.76
- BDRX 47.13
- Support Level
- ENTO $0.52
- BDRX $4.13
- Resistance Level
- ENTO $0.62
- BDRX $4.60
- Average True Range (ATR)
- ENTO 0.06
- BDRX 0.25
- MACD
- ENTO -0.01
- BDRX 0.04
- Stochastic Oscillator
- ENTO 11.11
- BDRX 55.15
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.